Effect of coenzyme Q10 versus placebo on the prevention of contrast medium-induced nephropathy in patients undergoing primary angioplasty

Phase 3

Recruiting

• Conditions: Angioplasty.; Angioplasty status; Z98.6

• Registration Number: IRCT20120215009014N414
• Lead Sponsor: Hamedan University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 11 January 2022

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

Age 18 to 75 years;
Symptoms of persistent myocardial ischemia for at least 30 minutes;
Less than 12 hours after the onset of heart attack symptoms;
Increased ST segment on electrocardiogram;
Treated with primary angioplasty;

Exclusion Criteria

Consumption of any antioxidants in the past month;
Indication of cardiac bypass surgery;
History of myocardial infarction or angioplasty;
Indication of thrombolytic therapy;
Cardiogenic shock;
History of heart failure;
Advanced liver failure or autoimmune or inflammatory diseases

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
ephropathy. Timepoint: Before the intervention and 24, 48, 72 hours after the intervention. Method of measurement: By measuring serum levels of BUN, creatinine and Estimated glomerular filtration rate (eGFR).

Secondary Outcome Measures

Name	Time	Method
Serum level of CRP. Timepoint: Before the intervention and 24, 48, 72 hours. Method of measurement: After the intervention by laboratory test.